食品伙伴網(wǎng)報道，根據(jù)美國營養(yǎng)成分網(wǎng)8月20日消息稱，中國嚴厲的安全規(guī)則和成熟的消費者市場已經(jīng)促使該國內(nèi)的海洋生物產(chǎn)業(yè)上加大了投資。國外的保健品公司將中國市場作為“機遇之窗”。

    海南魁北克海洋漁業(yè)有限公司（HQ Sustainable Maritime Industries）上周已確認對其已被中國認證的Jiahua子公司注入了1150萬美元的資金，以便抓住這個“機遇之窗”。該企業(yè)稱，在中國，由于“宏觀調控和社會經(jīng)濟學發(fā)展趨勢相結合，為之提供了廣闊的企業(yè)對企業(yè)和企業(yè)對消費者的發(fā)展前景，而這些則體現(xiàn)在來自羅非魚和非瀕危鯊魚的的副產(chǎn)品，如鯊魚軟骨膠囊、鯊魚魚肝油等產(chǎn)品。

    HQ稱，中國市場的機遇是由新的安全立法所驅動的。將直接或間接向消費者銷售不合格產(chǎn)品視為刑事犯罪。而此舉導致中國國內(nèi)1/3的保健品生產(chǎn)商停業(yè)。并且中國目前已經(jīng)成為了一個老齡化社會，到2050年，根據(jù)世衛(wèi)組織的報告，中國24%的人口將65歲以上，這意味著將有3億名65歲以上的老人。這個市場是巨大的。
 

原文報道： 20-Aug-2010

The tightening of safety rules in China and a ripe consumer market has prompted heavy investment in the country from a US-based producer of marine-biomass products.

HQ Sustainable Maritime Industries last week confirmed an injection of $11.5m into its Jiahua subsidiary in order to develop the “immediate window of opportunity” it has identified in the country.

According to the firm, a combination of “macro-regulatory and socio-economic trends” in China provide a fertile landscape for the growth of both its B2B and B2C operations, which are focused on the supply of fish by-products from tilapia and non-endangered shark. These include shark cartilage capsules and shark liver oil products.

Competitors down, consumers up

HQ said the Chinese market opportunity is driven by new safety legislation which “made it a criminal offence to manufacture or certify substandard products for direct or indirect human consumption. This led to the closure of almost one-third of the nutraceutical manufacturers in China”.

In addition, the firm believes the population demographics are currently strong for its business, with a key target for the company’s products being elderly consumers.

It notes “an aging China population, with an estimated 24 percent to be over the age of 65 by 2050, according to the World Health Organization. This will represent roughly 300 million people over the age of 65”.

Vertical integration

HQ said it has raised $11.5m in equity financing “to be fully utilized to develop this opportunity”.

The firm says its long-term goal is to “become the world leader in vertically integrated production, processing and raising of all natural tilapia products”.

“This includes the use of tilapia by-products to increase the range and variety of our marine bio and healthcare products, with a primary focus on increasing our own seafood products.”

原文地址：http://www.nutraingredients-usa.com/Industry/Nutraceutical-firm-targets-Chinese-window-of-opportunity